Bromperidol, a New Butyrophenone Neuroleptic: a Review

Overview

Journal Psychopharmacology (Berl)

Specialty Pharmacology

Date 1982 Jan 1

PMID 6128755

Citations 4

Authors

B DUBINSKY

J L Mcguire

C J NIEMEGEERS

P A Janssen

H S Weintraub

B E McKenzie

Affiliations

Soon will be listed here.

Abstract

This review compares and contrasts the preclinical pharmacology of bromperidol with another butyrophenone neuroleptic, haloperidol, and the phenothiazine neuroleptic chlorpromazine. Its pharmacokinetics, biotransformation, and safety in several laboratory animal species are also summarized. These preclinical data support its use as an antipsychotic agent and show that it is well absorbed following oral administration with an apparent elimination half-life of approximately 24 h, supporting a once-daily dose regimen. Animal toxicity (including acute- and multiple-dose toxicology and reproductive and mutagenicity studies) show that bromperidol is well tolerated.

Citing Articles

Heterocyclic Antidepressants with Antimicrobial and Fungicide Activity.

Zolotareva D, Zazybin A, Belyankova Y, Bayazit S, Dauletbakov A, Seilkhanov T Molecules. 2025; 30(5).

PMID: 40076325 PMC: 11902072. DOI: 10.3390/molecules30051102.

Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and Future.

Li P, Snyder G, Vanover K Curr Top Med Chem. 2016; 16(29):3385-3403.

PMID: 27291902 PMC: 5112764. DOI: 10.2174/1568026616666160608084834.

Zebrafish behavioral profiling identifies multitarget antipsychotic-like compounds.

Bruni G, Rennekamp A, Velenich A, McCarroll M, Gendelev L, Fertsch E Nat Chem Biol. 2016; 12(7):559-66.

PMID: 27239787 PMC: 4912417. DOI: 10.1038/nchembio.2097.

Conditioned taste aversion to chlorpromazine, but not to haloperidol.

Giardini V Psychopharmacology (Berl). 1985; 86(1-2):81-3.

PMID: 3927369 DOI: 10.1007/BF00431688.

Bromperidol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in psychoses.

Benfield P, Ward A, Clark B, Jue S Drugs. 1988; 35(6):670-84.

PMID: 3048975 DOI: 10.2165/00003495-198835060-00004.

References

Snyder S . Catecholamines in the brain as mediators of amphetamine psychosis. Arch Gen Psychiatry. 1972; 27(2):169-79. DOI: 10.1001/archpsyc.1972.01750260021004. View

Bennett Jr J, Snyder S . Stereospecific binding of D-lysergic acid diethylamide (LSD) to brain membranes: relationship to serotonin receptors. Brain Res. 1975; 94(3):523-44. DOI: 10.1016/0006-8993(75)90234-6. View

NIEMEGEERS C, Lenaerts F, Artois K, Janssen P . Interaction of drugs with apomorphine, tryptamine and norepinephrine. A new 'in vivo' approach: the ATN-test in rats. Arch Int Pharmacodyn Ther. 1977; 227(2):238-53. View

Marsboom R . [Toxicologic studies on butyrophenone neuroleptics and related substances]. Int Pharmacopsychiatry. 1978; 13 Suppl 1:3-14. View

HAASE H, Kaumeier S, Schwarz H, Gundel A, Linde O, Maetz H . Open study with bromperidol (C-C 2489), a new neuroleptic, for the determination of the neuroleptic threshold and the neuroleptic-therapeutic range. Pharmakopsychiatr Neuropsychopharmakol. 1978; 11(2):81-5. DOI: 10.1055/s-0028-1094566. View

Chasseaud L . Metabolic fate of bromperidol in humans: comparison with rats and dogs. Acta Psychiatr Belg. 1978; 78(1):51-63. View

Creese I, Burt D, Snyder S . Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science. 1976; 192(4238):481-3. DOI: 10.1126/science.3854. View

Creese I, Burt D, Snyder S . Dopamine receptor binding: differentiation of agonist and antagonist states with 3H-dopamine and 3H-haloperidol. Life Sci. 1975; 17(6):933-1001. DOI: 10.1016/0024-3205(75)90454-3. View

Van den Eeckhout E, Belpaire F, Bogaert M, de Moerloose P . Radioimmunoassay of bromperidol and haloperidol in human and canine plasma. Eur J Drug Metab Pharmacokinet. 1980; 5(1):45-8. DOI: 10.1007/BF03189443. View

10.

Poldinger W, Bures E, Haage H . Double-blind study with two butyrophenone derivatives: bromperidol vs. haloperidol. Int Pharmacopsychiatry. 1977; 12(3):184-92. DOI: 10.1159/000468306. View

11.

Poldinger W, Bures E, Haage H . Clinical study with bromperidol, a new butyrophenone derivative. Int Pharmacopsychiatry. 1977; 12(1):20-4. DOI: 10.1159/000468282. View

12.

Hermans B, Van Daele P, VAN DE WESTERINGH C, Van der Eycken C, Boey J, Janssen P . 4-Substituted piperidines. 3. Reduction of 1-benzyl-4-cyano-4-r-aminopiperidines with lithium albuminium hydride. J Med Chem. 1966; 9(1):49-52. DOI: 10.1021/jm00319a012. View

13.

NIEMEGEERS C, Janssen P . A systematic study of the pharmacological activities of dopamine antagonists. Life Sci. 1979; 24(24):2201-16. DOI: 10.1016/0024-3205(79)90096-1. View

14.

Janssen P, NIEMEGEERS C, SCHELLEKENS K . IS IT POSSIBLE TO PREDICT THE CLINICAL EFFECTS OF NEUROLEPTIC DRUGS (MAJOR TRANQUILLIZERS) FROM ANIMAL DATA?I. "NEUROLEPTIC ACTIVITY SPECTRA" FOR RATS. Arzneimittelforschung. 1965; 15:104-17. View

15.

Janssen P, NIEMEGEERS C, Jageneau A . Apomorphine-antagonism in rats. Arzneimittelforschung. 1960; 10:1003-5. View

16.

Creese I, Feinberg A, Snyder S . Butyrophenone influences on the opiate receptor. Eur J Pharmacol. 1976; 36(1):231-5. DOI: 10.1016/0014-2999(76)90277-6. View

17.

Hermans B, Van Daele P, VAN DE WESTERINGH C, Van der Eycken C, Boey J, Janssen P . 4-substituted piperidines. II. Reaction of 1-benzyl-4-cyano-4-t-aminopiperidines with organometallic compounds. J Med Chem. 1965; 8(6):851-5. DOI: 10.1021/jm00330a027. View

18.

BARTHOLINI G . Differential effect of neuroleptic drugs on dopamine turnover in the extrapyramidal and limbic system. J Pharm Pharmacol. 1976; 28(5):429-33. DOI: 10.1111/j.2042-7158.1976.tb04648.x. View

19.

NIEMEGEERS C, Janssen P . Bromoperidol, a new potent neuroleptic of the butyrophenone series. Comparative pharmacology of bromoperidol and haloperidol. Arzneimittelforschung. 1974; 24(1):45-52. View

20.

NIEMEGEERS C, Laduron P, Janssen P . Pharmacology and biochemistry of bromperidol. Acta Psychiatr Belg. 1978; 78(1):37-50. View